CancerNetwork® sat down with David O’Malley, MD, at the 2021 European Society for Medical Oncology to talk about the OReO trial and how these findings impact what’s already known about PARP inhibitors for the treatment of ovarian cancer.
At the 2021 European Society for Medical Oncology Congress, CancerNetwork® spoke with David O’Malley, MD, of The Ohio State University College of Medicine, who said he was excited to see the results of the OreO trial (NCT03106987), which investigated olaparib (Lynparza) maintenance retreatment in ovarian cancer.
The OReO trial, which was presented [at ESMO and] showed the benefit of PARP inhibitors and platinum-sensitive recurrence in the maintenance setting, is interesting. Now, these improvements were modest. However, it did show that one of the best predictors of PARP response is the responsiveness to platinum [therapy]. We need a lot more information from this trial. There are a lot of questions we have [and] very small numbers of responses that we [are using to derive] the overall hazard ratio. For example, what wasn’t presented was the number of patients who had discontinued prior PARP exposure because of toxicity, progression, or [therapy completion]. Some patients had 2 years of treatment with SOLO-1 [NCT01844986] or 3 years with the PRIMA trial [NCT02655016]. Clearly, the patient that does not progress on PARP versus the patient that progresses seems to be a much different patient population. We really need to look at those patients individually and get more information.
Pujade-Lauraine E, Selle F, Scambia G, et al. Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): phase IIIb OReO/ENGOT Ov-38 trial. Presented at: 2021 European Society for Medical Oncology Congress; September 16-21, 2021; Virtual. Abstract LBA33.